Federal
regulators have warned more than 350 medical practices that Botox they may have
received from a Canadian supplier is unapproved and could be counterfeit or
unsafe.
The
Food and Drug Administration said in a letter sent last month, a letter
released publicly last week, that batches of the wrinkle treatment shipped by
suppliers owned by pharmacy Canada Drugs have not been approved by the FDA and
that the agency cannot assure their effectiveness or their safety.
The
FDA said Canada Drugs was previously tied to shipping unapproved and
counterfeit cancer drugs.
The
agency warned doctors about buying drugs from sources other than licensed U.S.
pharmacies. It is the fifth warning the agency has made this year about foreign
suppliers providing unapproved drugs.
In
February, the agency warned 19 medical practices that they had received a
counterfeit version of the cancer drug Avastin. On three more occasions the FDA
issued similar warnings about counterfeit Avastin and Altuzan, another brand
name for the same drug. The alerts were also primarily targeted at drugs
distributed by Canada Drugs.
A
request for comment from the drug distributor was not immediately returned.
Drug
shortages increased the financial incentives for some pharmacies to provide
counterfeit or illegally imported drugs. The drugs subject to warnings have all
been injectable treatments typically distributed through medical practices and
not directly to patients.
In
October, the FDA ordered operators of about 4,100 websites to immediately stop
selling unapproved medications to U.S. consumers. The vast majority of those
sites were operated by Canada Drugs. The site was still operating Friday.
Genuine
Botox is made by Allergan Inc., based in Irvine, Calif. Avastin is made by
Roche Holding AG's Genentech unit.
Check out the ABC article here.
No comments:
Post a Comment